Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

AnorMED completes public offering of US$100 million

Reading Time 1 minute read Subscribe

AnorMED Inc.

Represented AnorMED Inc., a local biotechnology company, in connection with three bought deal short form prospectus offerings and a special warrant prospectus offering, and in connection with its initial public offering and listing of its Common Shares on the Toronto Stock Exchange totaling more than $100 million.


    Receive email updates from our team